Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sally Johnson

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 22, 2025
Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUSGiovany Orozco-Leal, Luke Vale, Yemi Oluboyede, et al.
BMJ Open|September 19, 2022
Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm studySarah Dunn, Victoria Brocklebank, Andrew Bryant, et al.
Kidney International|June 17, 2018
Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcomeFranz Schaefer, Gianluigi Ardissino, Gema Ariceta, et al.
Blood|June 27, 2023
Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort studyVicky Brocklebank, Patrick R Walsh, Kate Smith-Jackson, et al.
Pediatric Nephrology (Berlin, Germany)|May 13, 2014
An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndromeSally Johnson, Jelena Stojanovic, Gema Ariceta, et al.
The Lancet Regional Health. Europe|January 19, 2026
Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trialAndrew Bryant, Jan Lecouturier, Giovany Orozco-Leal, et al.
Brain Communications|August 23, 2021
Identification of <i>LAMA1</i> mutations ends diagnostic odyssey and has prognostic implications for patients with presumed Joubert syndromeLaura Powell, Eric Olinger, Sarah Wedderburn, et al.
Pediatric Nephrology (Berlin, Germany)|April 11, 2015
An international consensus approach to the management of atypical hemolytic uremic syndrome in childrenChantal Loirat, Fadi Fakhouri, Gema Ariceta, et al.
Kidney International|October 12, 2024
Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International ForumDavid Kavanagh, Gianluigi Ardissino, Vicky Brocklebank, et al.
Kidney International|July 29, 2017
Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and IrelandVicky Brocklebank, Sally Johnson, Thomas P Sheerin, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 22, 2025
Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUSGiovany Orozco-Leal, Luke Vale, Yemi Oluboyede, et al.
BMJ Open|September 19, 2022
Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm studySarah Dunn, Victoria Brocklebank, Andrew Bryant, et al.
Kidney International|June 17, 2018
Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcomeFranz Schaefer, Gianluigi Ardissino, Gema Ariceta, et al.
Blood|June 27, 2023
Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort studyVicky Brocklebank, Patrick R Walsh, Kate Smith-Jackson, et al.
Pediatric Nephrology (Berlin, Germany)|May 13, 2014
An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndromeSally Johnson, Jelena Stojanovic, Gema Ariceta, et al.
The Lancet Regional Health. Europe|January 19, 2026
Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trialAndrew Bryant, Jan Lecouturier, Giovany Orozco-Leal, et al.
Brain Communications|August 23, 2021
Identification of <i>LAMA1</i> mutations ends diagnostic odyssey and has prognostic implications for patients with presumed Joubert syndromeLaura Powell, Eric Olinger, Sarah Wedderburn, et al.
Pediatric Nephrology (Berlin, Germany)|April 11, 2015
An international consensus approach to the management of atypical hemolytic uremic syndrome in childrenChantal Loirat, Fadi Fakhouri, Gema Ariceta, et al.
Kidney International|October 12, 2024
Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International ForumDavid Kavanagh, Gianluigi Ardissino, Vicky Brocklebank, et al.
Kidney International|July 29, 2017
Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and IrelandVicky Brocklebank, Sally Johnson, Thomas P Sheerin, et al.
Pageof 5